Exparel, Posimir (bupivacaine) is a small molecule pharmaceutical. Bupivacaine was first approved as Exparel on 2011-10-28. It is used to treat postoperative pain in the USA. It has been approved in Europe to treat acute pain. It is known to target G protein-activated inward rectifier potassium channel 2, potassium voltage-gated channel subfamily D member 3, potassium voltage-gated channel subfamily A member 5, and sodium channel protein type 5 subunit alpha. Bupivacaine hydrochloride and epinephrine's patents are valid until 2041-01-22 (FDA).
|Trade Name||Exparel liposomal|
|Indication||acute pain, postoperative pain|
|Drug Class||Local anesthetics|